Sara Lustigman

InstitutionNew York Blood Center
AddressNew York
New York
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 2 Covid-19 publications, with a maximum of 1 publications in May 2020 and Spetember 2020
    All Publications
    Bar chart showing 92 publications over 20 distinct years, with a maximum of 11 publications in 2012
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chen WH, Tao X, Agrawal AS, Algaissi A, Peng BH, Pollet J, Strych U, Bottazzi ME, Hotez PJ, Lustigman S, Du L, Jiang S, Tseng CK. Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541. PMID: 33039209.
      Citations: 24     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    2. George PJ, Tai W, Du L, Lustigman S. The Potency of an Anti-MERS Coronavirus Subunit Vaccine Depends on a Unique Combinatorial Adjuvant Formulation. Vaccines (Basel). 2020 May 27; 8(2). PMID: 32471056.
      Citations: 4     
    3. Hotez PJ, Bottazzi ME, Tseng CT, Zhan B, Lustigman S, Du L, Jiang S. Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31. PMID: 24931059.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    4. Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, Seid CA, Hudspeth EM, Lustigman S, Tseng CT, Bottazzi ME, Hotez PJ, Zhan B, Jiang S. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58. PMID: 24355931.
      Citations: 49     Fields:    Translation:AnimalsCells
    5. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, Jones K, Zhan B, Hotez PJ. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13. PMID: 23252385.
      Citations: 58     Fields:    Translation:HumansAnimalsCells
    6. Wang J, Tricoche N, Du L, Hunter M, Zhan B, Goud G, Didier ES, Liu J, Lu L, Marx PA, Jiang S, Lustigman S. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012; 7(5):e37019. PMID: 22615877.
      Citations: 18     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    7. He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, Lustigman S. Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol. 2009 Apr 01; 182(7):4005-16. PMID: 19299698.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    8. He Y, Li J, Heck S, Lustigman S, Jiang S. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol. 2006 Jun; 80(12):5757-67. PMID: 16731915.
      Citations: 63     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    9. He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006 May 15; 176(10):6085-92. PMID: 16670317.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    10. MacDonald AJ, Cao L, He Y, Zhao Q, Jiang S, Lustigman S. rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine. 2005 May 16; 23(26):3446-52. PMID: 15837368.
      Citations: 14     Fields:    Translation:AnimalsCells